Abha Khandelwal, MD
Cardiovascular Disease (Cardiology) · Stanford
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 17
- 3 carriers
- Offices
- 4
Offices
4 locations · Stanford Health Care · 3,152 clinicians in this group
Looking this up.
Hospitals listed: Stanford Health Care. That is not proof they admit you there this week.
Plans that list them
17 plans · 3 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Khandelwal’s office to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
17 of 17 plans
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Silicon (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health smartHMO (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health the ONE (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| SCAN Balance (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Classic (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN MyChoice (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Strive (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| DualConnect (HMO D-SNP) | Santa Clara Family Health Plan | Listed | Sep 1, 2026 |
California Medical Board record
Licence A126558 · Current
Licensed to practise in California · since 2013 · expires 2026-11-30 · Ohio State University College of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
State licence records
1 licence
- Illinois 125049596Temporary Medical Permit · since 2005 · expires 2008-06-30Specialty on the licence: Internal MedicineCancelledNo board action on this licenceCheck it with the state
We check Colorado, Delaware, Florida, Illinois, Maryland, New Jersey, New York, Tennessee, Texas, Virginia, Washington, plus California above. A state that is not in this list has not been checked, which is not the same as clear.
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for Stanford Health Care
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.31 (4.24 to 6.37) · 8,661 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 14.1 (12.7 to 15.7) · 2,191 cases | Worse | Jan 2024 – Dec 2024 |
| Postoperative respiratory failure rateComplications and deaths | 4.08 (1.95 to 6.21) · 5,296 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.317 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.446 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.241 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.7 (0.6 to 0.9) · 3,348 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.06 (0.45 to 1.67) · 5,374 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.86 (0.72 to 1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 166.09 (137.88 to 194.3) · 470 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.1 · 192 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.4 · 146 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.7 · 253 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.3 · 880 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 935 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 501 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.1 · 7,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.27) · 20,799 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.14 to 0.43) · 23,182 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.94 (0.2 to 1.68) · 5,694 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.36 (1.54 to 3.19) · 7,846 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.2 (3.76 to 6.64) · 5,603 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.38 (0.23 to 2.53) · 2,211 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.52 (0.21 to 0.83) · 19,915 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.6 · 416 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.869 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.857 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.368 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16.2 · 247 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.5 · 1,021 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 47.8 · 258 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -1.6 · 990 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 20.8 · 976 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.5 · 959 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (4.4 to 6.2) · 2,191 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 425 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.6 · 158 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 183 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.7 (10.4 to 15.4) · 4,578 cases | No different | Jan 2022 – Dec 2024 |
What patients said (6,810 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 83% |
| Staff "always" explained possible side effects | 50% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$103,137
Medicare paid this office $103,137 for 1,479 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 499 | $30,132 | $59 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 89 | $12,744 | $143 |
| Long return visit (40+ min) | 54 | $8,079 | $126 |
| Return visit (30+ min) | 77 | $7,361 | $83 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 44 | $5,494 | $112 |
See all 23 services
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 499 | $30,132 | $59 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 89 | $12,744 | $143 |
| Long return visit (40+ min) | 54 | $8,079 | $126 |
| Return visit (30+ min) | 77 | $7,361 | $83 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 44 | $5,494 | $112 |
| Ultrasound of heart with probe in esophagus, with report | 56 | $5,284 | $91 |
| Initial hospital care with straightforward or low level of medical decision making, per day at least 40 minutes | 46 | $4,182 | $73 |
| Return visit (30+ min) | 23 | $2,971 | $124 |
| Ultrasound of heart, follow-up | 114 | $2,624 | $22 |
| New patient visit (60+ min) | 17 | $2,534 | $149 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 19 | $2,471 | $71 |
| Ultrasound of heart during rest, exercise and/or drug-induced stress with report | 44 | $2,366 | $54 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 296 | $2,212 | $7 |
| Long return visit (40+ min) | 11 | $2,074 | $173 |
| Ultrasound of heart, follow-up | 27 | $1,615 | $60 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision by physician | 83 | $1,441 | $17 |
| Heart rhythm review and interpretation of continous external ekg over 8-15 days | 57 | $1,250 | $22 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with review by physician | 93 | $1,086 | $12 |
| Ultrasound of heart blood flow, valves and chambers, follow-up | 151 | $984 | $6 |
| Ultrasound of heart with continuous electrocardiogram (ecg) during rest, exercise and/or drug induced stress with review and report | 11 | $725 | $66 |
| Ultrasound of heart blood flow, valves and chambers | 38 | $538 | $14 |
| Ultrasound of heart blood flow, valves and chambers, follow-up | 29 | $498 | $17 |
| Ultrasound of heart with color-depicted blood flow, rate and valve function | 81 | $218 | $3 |
Who their Medicare patients are
1,479 Original Medicare patients in 2024. Average age 75 · Under 65 9% · 85 and older 17% · Women 48% · Also on Medicaid 26% · Health risk score 2.09. Above the middle of the specialty; the typical cardiology clinician is at 1.71.
Conditions among them: High blood pressure 75% · Coronary heart disease 53% · Atrial fibrillation 47% · Heart failure 45% · Chronic kidney disease 44% · Diabetes 37% · Depression 23% · Cancer 22% · COPD 20% · Stroke 19% · Dementia 15%.
The office billed $861,007, Medicare allowed $136,694 and paid $103,137; for 2,156 services of 35 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 1,479 | 2,156 | 75 | 2.09 | $861,007 | $103,137 |
| 2023 | 1,171 | 1,905 | 75 | 2.10 | $679,394 | $89,530 |
| 2022 | 1,603 | 2,461 | 75 | 2.14 | $780,445 | $100,304 |
| 2021 | 1,699 | 2,929 | 74 | 1.99 | $903,498 | $131,898 |
| 2020 | 1,166 | 2,013 | 73 | 2.18 | $656,268 | $96,869 |
| 2019 | 1,484 | 2,386 | 74 | 2.22 | $440,781 | $85,439 |
| 2018 | 805 | 1,399 | 74 | 1.89 | $305,864 | $68,431 |
| 2017 | 654 | 1,064 | 74 | 1.95 | $196,264 | $48,814 |
| 2016 | 1,684 | 2,770 | 73 | 2.09 | $350,435 | $69,032 |
| 2015 | 1,254 | 1,892 | 73 | 1.98 | $228,317 | $47,766 |
| 2014 | 732 | 1,085 | 74 | 1.67 | $192,746 | $47,955 |
| 2013 | 56 | 67 | 72 | 1.43 | $26,081 | $7,807 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 20 services
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 481 | $27,973 | $57 |
| Long return visit (40+ min) | 72 | $10,477 | $125 |
| Return visit (30+ min) | 82 | $8,087 | $86 |
| New patient visit (60+ min) | 38 | $5,546 | $146 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 38 | $5,300 | $139 |
| Ultrasound of heart with probe in esophagus, with report | 50 | $4,896 | $98 |
| Ultrasound of heart during rest, exercise and/or drug-induced stress with report | 69 | $4,132 | $60 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 16 | $3,210 | $73 |
| Ultrasound of heart, follow-up | 134 | $3,052 | $22 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision by physician | 138 | $2,674 | $19 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 17 | $2,152 | $120 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with review by physician | 154 | $1,948 | $13 |
| Ultrasound of heart, follow-up | 18 | $1,289 | $72 |
| Heart rhythm review and interpretation of continous external ekg over 8-15 days | 45 | $1,077 | $24 |
| Ultrasound of heart blood flow, valves and chambers, follow-up | 163 | $1,055 | $6 |
| Short return visit (20+ min) | 13 | $793 | $61 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 101 | $785 | $7 |
| Ultrasound of heart blood flow, valves and chambers | 45 | $718 | $16 |
| Ultrasound of heart blood flow, valves and chambers, follow-up | 17 | $325 | $19 |
| Ultrasound of heart with color-depicted blood flow, rate and valve function | 77 | $220 | $3 |
2022: 21 services
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 677 | $39,655 | $57 |
| Long return visit (40+ min) | 69 | $9,375 | $116 |
| Return visit (30+ min) | 66 | $6,723 | $86 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 66 | $6,185 | $94 |
| Ultrasound of heart with probe in esophagus, with report | 61 | $5,676 | $93 |
| Ultrasound of heart during rest, exercise and/or drug-induced stress with report | 72 | $4,311 | $60 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 28 | $4,284 | $65 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 423 | $3,316 | $7 |
| Ultrasound of heart, follow-up | 121 | $2,782 | $22 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 21 | $2,581 | $123 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision by physician | 129 | $2,471 | $19 |
| New patient visit (60+ min) | 13 | $2,154 | $166 |
| Initial hospital care with straightforward or low level of medical decision making, per day at least 40 minutes | 20 | $1,805 | $90 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with review by physician | 129 | $1,680 | $13 |
| Heart rhythm review and interpretation of continous external ekg over 8-15 days | 41 | $1,101 | $25 |
| Ultrasound of heart blood flow, valves and chambers, follow-up | 157 | $1,026 | $6 |
| Hospital discharge day management, 30 minutes or less | 11 | $754 | $69 |
| Ultrasound of heart blood flow, valves and chambers | 42 | $672 | $16 |
| Ultrasound of heart, follow-up | 11 | $658 | $60 |
| Ultrasound of heart with color-depicted blood flow, rate and valve function | 96 | $265 | $3 |
| Ultrasound of heart blood flow, valves and chambers, follow-up | 11 | $173 | $16 |
2021: 19 services
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 759 | $47,869 | $61 |
| Long return visit (40+ min) | 81 | $11,409 | $123 |
| Ultrasound of heart during rest, exercise and/or drug-induced stress with report | 141 | $8,662 | $61 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 60 | $7,567 | $124 |
| Return visit (30+ min) | 82 | $7,444 | $85 |
| New patient visit (60+ min) | 42 | $7,367 | $175 |
| Ultrasound of heart with probe in esophagus, with report | 66 | $6,764 | $101 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision by physician | 282 | $5,401 | $19 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 30 | $3,884 | $125 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with review by physician | 281 | $3,630 | $13 |
| Ultrasound of heart, follow-up | 143 | $3,451 | $23 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 27 | $3,054 | $66 |
| Initial hospital care with straightforward or low level of medical decision making, per day at least 40 minutes | 25 | $2,580 | $92 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 249 | $2,066 | $8 |
| Heart rhythm review and interpretation of continous external ekg over 8-15 days | 57 | $1,552 | $25 |
| Ultrasound of heart blood flow, valves and chambers | 86 | $1,338 | $16 |
| Ultrasound of heart blood flow, valves and chambers, follow-up | 156 | $1,079 | $7 |
| Hospital discharge day management, 30 minutes or less | 14 | $951 | $68 |
| Ultrasound of heart with color-depicted blood flow, rate and valve function | 132 | $370 | $3 |
2020: 21 services
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 551 | $35,998 | $64 |
| Return visit (30+ min) | 119 | $9,702 | $65 |
| Ultrasound of heart during rest, exercise and/or drug-induced stress with report | 93 | $5,702 | $61 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 45 | $5,471 | $68 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 34 | $4,553 | $130 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision by physician | 198 | $3,947 | $20 |
| Ultrasound of heart with probe in esophagus, with report | 33 | $3,507 | $103 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 31 | $3,451 | $108 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with review by physician | 198 | $2,659 | $13 |
| Long return visit (40+ min) | 22 | $2,233 | $97 |
| Initial hospital care with straightforward or low level of medical decision making, per day at least 40 minutes | 22 | $2,076 | $94 |
| Hospital discharge day management, 30 minutes or less | 27 | $1,876 | $69 |
| Ultrasound of heart, follow-up | 72 | $1,678 | $23 |
| New patient visit (60+ min) | 11 | $1,579 | $144 |
| Review and interpretation of external ekg recording for more than 48 hours up to 21 days | 62 | $1,566 | $23 |
| Initial hospital observation care per day, typically 50 minutes | 11 | $1,349 | $123 |
| Return visit (30+ min) | 14 | $1,005 | $72 |
| Ultrasound of heart blood flow, valves and chambers | 56 | $917 | $16 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 69 | $603 | $8 |
| Ultrasound of heart blood flow, valves and chambers, follow-up | 75 | $500 | $6 |
| Ultrasound of heart with color-depicted blood flow, rate and valve function | 73 | $214 | $3 |
2019: 20 services
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 439 | $28,245 | $62 |
| Return visit (30+ min) | 148 | $14,282 | $65 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 567 | $5,108 | $8 |
| Ultrasound of heart during rest, exercise and/or drug-induced stress with report | 78 | $4,784 | $61 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision by physician | 199 | $3,969 | $20 |
| Ultrasound of heart with probe in esophagus, with report | 33 | $3,185 | $97 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 30 | $2,838 | $66 |
| Initial hospital care with straightforward or low level of medical decision making, per day at least 40 minutes | 30 | $2,816 | $91 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with review by physician | 197 | $2,644 | $13 |
| Long return visit (40+ min) | 22 | $2,503 | $86 |
| New patient visit (60+ min) | 14 | $2,081 | $149 |
| New patient visit (45+ min) | 19 | $1,866 | $98 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 14 | $1,733 | $124 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 21 | $1,476 | $67 |
| Review and interpretation of external ekg recording for more than 48 hours up to 21 days | 51 | $1,373 | $25 |
| Ultrasound of heart, follow-up | 55 | $1,255 | $22 |
| Ultrasound of heart blood flow, valves and chambers | 47 | $757 | $16 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 12 | $568 | $36 |
| Ultrasound of heart blood flow, valves and chambers, follow-up | 43 | $275 | $6 |
| Ultrasound of heart with color-depicted blood flow, rate and valve function | 72 | $203 | $3 |
2018: 20 services
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 360 | $21,955 | $60 |
| Return visit (30+ min) | 143 | $13,697 | $65 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 37 | $3,791 | $65 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision by physician | 171 | $3,284 | $19 |
| Ultrasound of heart during rest, exercise and/or drug-induced stress with report | 52 | $3,120 | $60 |
| New patient visit (45+ min) | 25 | $2,781 | $111 |
| Long return visit (40+ min) | 27 | $2,583 | $86 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with review by physician | 171 | $2,237 | $13 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 17 | $2,078 | $122 |
| New patient visit (60+ min) | 11 | $1,656 | $151 |
| Ultrasound of heart with probe in esophagus, with report | 16 | $1,581 | $99 |
| Hospital discharge day management, 30 minutes or less | 20 | $1,337 | $67 |
| Initial hospital care with straightforward or low level of medical decision making, per day at least 40 minutes | 12 | $1,078 | $90 |
| Short return visit (20+ min) | 28 | $876 | $31 |
| Review and interpretation of external ekg recording for more than 48 hours up to 21 days | 29 | $711 | $25 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 12 | $645 | $54 |
| Ultrasound of heart, follow-up | 18 | $466 | $22 |
| Ultrasound of heart blood flow, valves and chambers | 28 | $451 | $16 |
| Ultrasound of heart with color-depicted blood flow, rate and valve function | 43 | $122 | $3 |
| Ultrasound of heart blood flow, valves and chambers, follow-up | 13 | $86 | $6 |
2017: 15 services
| Return visit (30+ min) | 120 | $11,247 | $66 |
| New patient visit (45+ min) | 53 | $5,920 | $112 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 46 | $4,859 | $64 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 71 | $3,929 | $55 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 23 | $2,807 | $122 |
| Initial hospital care with straightforward or low level of medical decision making, per day at least 40 minutes | 26 | $2,254 | $87 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 244 | $2,070 | $7 |
| Long return visit (40+ min) | 20 | $1,993 | $100 |
| Review and interpretation of external ekg recording for more than 48 hours up to 21 days | 79 | $1,983 | $24 |
| Hospital discharge day management, 30 minutes or less | 25 | $1,656 | $66 |
| Short return visit (20+ min) | 29 | $1,141 | $39 |
| Return visit (30+ min) | 13 | $855 | $66 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision by physician | 45 | $822 | $18 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 15 | $803 | $35 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with review by physician | 45 | $552 | $12 |
2016: 21 services
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 1,236 | $12,512 | $7 |
| Return visit (30+ min) | 89 | $8,158 | $61 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 96 | $5,615 | $57 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 40 | $5,503 | $64 |
| Return visit (30+ min) | 59 | $5,019 | $60 |
| New patient visit (45+ min) | 40 | $4,496 | $112 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 31 | $3,888 | $121 |
| Initial hospital care with straightforward or low level of medical decision making, per day at least 40 minutes | 35 | $3,123 | $89 |
| Initial hospital observation care per day, typically 50 minutes | 17 | $1,955 | $115 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 44 | $1,945 | $44 |
| Review and interpretation of external ekg recording for more than 48 hours up to 21 days | 72 | $1,804 | $24 |
| Long return visit (40+ min) | 17 | $1,685 | $99 |
| Hospital discharge day management, 30 minutes or less | 21 | $1,381 | $66 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision by physician | 67 | $1,341 | $20 |
| New patient visit (45+ min) | 12 | $1,183 | $99 |
| Short return visit (20+ min) | 24 | $1,139 | $46 |
| Hospital observation care on day of discharge | 14 | $922 | $66 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with review by physician | 68 | $888 | $13 |
| Ultrasound of heart during rest, exercise and/or drug-induced stress with report | 13 | $774 | $60 |
| Short return visit (20+ min) | 15 | $724 | $43 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 11 | $628 | $35 |
2015: 14 services
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 970 | $9,874 | $7 |
| Long return visit (40+ min) | 76 | $8,861 | $89 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 27 | $4,531 | $65 |
| Return visit (30+ min) | 52 | $3,796 | $64 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 31 | $3,680 | $119 |
| Review and interpretation of external ekg recording for more than 48 hours up to 21 days | 113 | $2,596 | $23 |
| New patient visit (45+ min) | 25 | $2,471 | $99 |
| Return visit (30+ min) | 23 | $2,303 | $74 |
| Initial hospital observation care per day, typically 50 minutes | 17 | $2,066 | $122 |
| Long return visit (40+ min) | 14 | $1,574 | $105 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 24 | $1,260 | $52 |
| Hospital discharge day management, 30 minutes or less | 18 | $1,192 | $66 |
| Initial hospital care with straightforward or low level of medical decision making, per day at least 40 minutes | 13 | $1,169 | $90 |
| Hospital observation care on day of discharge | 15 | $990 | $66 |
2014: 9 services
| Long return visit (40+ min) | 90 | $15,931 | $97 |
| New patient visit (45+ min) | 75 | $8,181 | $109 |
| Return visit (30+ min) | 29 | $5,650 | $78 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 454 | $3,967 | $8 |
| Review and interpretation of external ekg recording for more than 48 hours up to 21 days | 107 | $2,487 | $23 |
| New patient visit (60+ min) | 18 | $2,262 | $126 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 16 | $1,947 | $122 |
| Return visit (30+ min) | 20 | $1,399 | $70 |
| Hospital discharge day management, 30 minutes or less | 18 | $1,179 | $65 |
2013: 3 services
| New patient visit (60+ min) | 17 | $2,460 | $145 |
| New patient visit (45+ min) | 12 | $1,351 | $113 |
| Long return visit (40+ min) | 11 | $1,144 | $95 |
Medicaid work
$38,496 in 2024
Medicaid paid $38,496 for 830 billed services this clinician did in 2024, up to 148 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, complete, with spectral Doppler echocardiography, and with color flow Doppler echocardiography | 406 | $32,818 |
| Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | 267 | $3,086 |
| ECHO TRANSTHORC R-T 2D W/WO M-MODE REC F-UP/LMTD | 47 | $1,269 |
| DOPPLER ECHO PULSE WAVE W/SPECTRAL F-UP/LMTD STD | 57 | $661 |
| CARDIOVASCULAR STRESS TEST | 16 | $242 |
| Doppler echocardiography color flow velocity mapping (List separately in addition to codes for echocardiography) | 24 | $235 |
| CARDIOVASCULAR STRESS TEST | 13 | $186 |
| 2024 | 830 | 7 | 148 | $38,496 |
| 2023 | 794 | 8 | 93 | $37,310 |
| 2022 | 927 | 6 | 79 | $27,236 |
| 2021 | 1,129 | 6 | 118 | $37,789 |
| 2020 | 452 | 6 | 66 | $18,681 |
| 2019 | 605 | 5 | 72 | $15,411 |
| 2018 | 76 | 1 | 18 | $4,578 |
See the largest Medicaid services in earlier years
2023
| Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, complete, with spectral Doppler echocardiography, and with color flow Doppler echocardiography | 351 | $21,756 |
| Long return visit (40+ min) | 106 | $6,084 |
| New patient visit (60+ min) | 46 | $4,618 |
| ECHO TRANSTHORC R-T 2D W/WO M-MODE REC F-UP/LMTD | 78 | $2,143 |
| Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | 100 | $1,024 |
| DOPPLER ECHO PULSE WAVE W/SPECTRAL F-UP/LMTD STD | 63 | $699 |
| CARDIOVASCULAR STRESS TEST | 24 | $601 |
| CARDIOVASCULAR STRESS TEST | 26 | $385 |
2022
| Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, complete, with spectral Doppler echocardiography, and with color flow Doppler echocardiography | 409 | $20,132 |
| Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | 337 | $3,511 |
| ECHO TRANSTHORC R-T 2D W/WO M-MODE REC F-UP/LMTD | 85 | $2,308 |
| DOPPLER ECHO PULSE WAVE W/SPECTRAL F-UP/LMTD STD | 72 | $845 |
| CARDIOVASCULAR STRESS TEST | 12 | $251 |
| CARDIOVASCULAR STRESS TEST | 12 | $188 |
2021
| Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, complete, with spectral Doppler echocardiography, and with color flow Doppler echocardiography | 528 | $29,238 |
| CARDIOVASCULAR STRESS TEST | 133 | $2,769 |
| Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | 233 | $2,362 |
| CARDIOVASCULAR STRESS TEST | 131 | $1,987 |
| ECHO TRANSTHORC R-T 2D W/WO M-MODE REC F-UP/LMTD | 49 | $938 |
| DOPPLER ECHO PULSE WAVE W/SPECTRAL F-UP/LMTD STD | 55 | $494 |
2020
| Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, complete, with spectral Doppler echocardiography, and with color flow Doppler echocardiography | 300 | $16,267 |
| Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | 75 | $893 |
| CARDIOVASCULAR STRESS TEST | 25 | $540 |
| ECHO TRANSTHORC R-T 2D W/WO M-MODE REC F-UP/LMTD | 14 | $413 |
| CARDIOVASCULAR STRESS TEST | 25 | $389 |
| DOPPLER ECHO PULSE WAVE W/SPECTRAL F-UP/LMTD STD | 13 | $179 |
2019
| Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, complete, with spectral Doppler echocardiography, and with color flow Doppler echocardiography | 204 | $10,190 |
| Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | 330 | $3,934 |
| CARDIOVASCULAR STRESS TEST | 29 | $520 |
| Return visit (30+ min) | 12 | $398 |
| CARDIOVASCULAR STRESS TEST | 30 | $370 |
2018
| Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, complete, with spectral Doppler echocardiography, and with color flow Doppler echocardiography | 76 | $4,578 |
Drugs they prescribed that Part D paid
$166,382
Pharmacies billed $166,382 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 843) in 2024. At or below the middle of the specialty; the typical cardiology clinician is at 0%.
715 generic and 128 brand-name prescriptions · $166,382 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Repatha Sureclick | 51 | $62,342 | $1,222 |
| Eliquis | 30 | $48,299 | $1,610 |
| Praluent | 15 | $10,439 | $696 |
| Rosuvastatin | 109 | $1,366 | $13 |
| Ezetimibe | 43 | $1,364 | $32 |
See all 17 drugs
| Repatha Sureclick | 51 | $62,342 | $1,222 |
| Eliquis | 30 | $48,299 | $1,610 |
| Praluent | 15 | $10,439 | $696 |
| Rosuvastatin | 109 | $1,366 | $13 |
| Ezetimibe | 43 | $1,364 | $32 |
| Metoprolol | 105 | $1,362 | $13 |
| Atorvastatin | 108 | $1,342 | $12 |
| Ranolazine Er | 15 | $1,031 | $69 |
| Losartan | 56 | $534 | $10 |
| Isosorbide Mononitrate Er | 16 | $479 | $30 |
| Diltiazem | 12 | $338 | $28 |
| Lisinopril | 33 | $325 | $10 |
| Metoprolol | 26 | $197 | $8 |
| Amlodipine Besylate | 44 | $178 | $4 |
| Hydrochlorothiazide | 13 | $101 | $8 |
| Spironolactone | 18 | $37 | $2 |
| Carvedilol | 17 | $14 | $1 |
Year by year
| 2024 | 843 | 140 | 0% (0) | 15% | $166,382 |
| 2023 | 861 | 147 | 0% (0) | 16% | $150,759 |
| 2022 | 831 | 148 | 0% (0) | 15% | $135,029 |
| 2021 | 997 | 156 | 0% (0) | 18% | $164,328 |
| 2020 | 929 | 165 | None | None | $111,572 |
| 2019 | 841 | 145 | None | 14% | $93,616 |
| 2018 | 1,090 | 154 | 0% (0) | 17% | $157,881 |
| 2017 | 1,003 | 154 | 0% (0) | 18% | $128,795 |
| 2016 | 891 | 132 | None | 22% | $70,588 |
| 2015 | 540 | 105 | 0% (0) | None | $37,421 |
| 2014 | 482 | 81 | 0% (0) | None | $25,586 |
| 2013 | 37 | 21 | None | None | $1,691 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 16 drugs
| Repatha Sureclick | 58 | $53,131 | $916 |
| Eliquis | 25 | $38,138 | $1,526 |
| Farxiga | 11 | $8,908 | $810 |
| Rosuvastatin | 120 | $3,202 | $27 |
| Atorvastatin | 122 | $1,654 | $14 |
| Metoprolol | 87 | $1,626 | $19 |
| Ezetimibe | 23 | $831 | $36 |
| Diltiazem | 12 | $544 | $45 |
| Losartan | 46 | $460 | $10 |
| Amlodipine Besylate | 52 | $445 | $9 |
| Lisinopril | 45 | $389 | $9 |
| Carvedilol | 27 | $314 | $12 |
| Metoprolol | 29 | $266 | $9 |
| Clopidogrel | 13 | $121 | $9 |
| Spironolactone | 15 | $109 | $7 |
| Hydrochlorothiazide | 16 | $49 | $3 |
2022: 16 drugs
| Eliquis | 41 | $58,696 | $1,432 |
| Repatha Sureclick | 35 | $30,783 | $880 |
| Rosuvastatin | 104 | $2,260 | $22 |
| Atorvastatin | 140 | $1,775 | $13 |
| Metoprolol | 81 | $1,277 | $16 |
| Diltiazem 24hr Er (Cd) | 12 | $997 | $83 |
| Ezetimibe | 17 | $709 | $42 |
| Lisinopril | 41 | $556 | $14 |
| Amlodipine Besylate | 56 | $550 | $10 |
| Carvedilol | 26 | $529 | $20 |
| Losartan | 49 | $499 | $10 |
| Metoprolol | 30 | $271 | $9 |
| Diltiazem | 14 | $270 | $19 |
| Hydralazine | 12 | $241 | $20 |
| Hydrochlorothiazide | 13 | $176 | $14 |
| Clopidogrel | 12 | $85 | $7 |
2021: 25 drugs
| Eliquis | 49 | $63,553 | $1,297 |
| Repatha Sureclick | 38 | $27,571 | $726 |
| Xarelto | 11 | $15,835 | $1,440 |
| Bystolic | 14 | $7,280 | $520 |
| Praluent | 14 | $6,827 | $488 |
| Atorvastatin | 160 | $2,486 | $16 |
| Ranolazine Er | 12 | $2,325 | $194 |
| Rosuvastatin | 86 | $2,270 | $26 |
| Metoprolol | 92 | $2,083 | $23 |
| Losartan | 71 | $986 | $14 |
| Ezetimibe | 14 | $957 | $68 |
| Valsartan | 12 | $871 | $73 |
| Diltiazem 24hr Er (Cd) | 11 | $619 | $56 |
| Amlodipine Besylate | 57 | $497 | $9 |
| Lisinopril | 45 | $475 | $11 |
| Isosorbide Mononitrate Er | 15 | $382 | $25 |
| Carvedilol | 25 | $374 | $15 |
| Sotalol | 14 | $327 | $23 |
| Metoprolol | 27 | $283 | $10 |
| Hydrochlorothiazide | 27 | $278 | $10 |
| Diltiazem | 12 | $246 | $20 |
| Hydralazine | 16 | $231 | $14 |
| Nitroglycerin | 14 | $227 | $16 |
| Clopidogrel | 15 | $141 | $9 |
| Furosemide | 16 | $133 | $8 |
2020: 19 drugs
| Eliquis | 35 | $42,563 | $1,216 |
| Bystolic | 21 | $10,398 | $495 |
| Praluent | 13 | $6,817 | $524 |
| Rosuvastatin | 72 | $3,195 | $44 |
| Metoprolol | 95 | $2,692 | $28 |
| Atorvastatin | 98 | $1,914 | $20 |
| Diltiazem 24hr Er (Cd) | 19 | $1,073 | $56 |
| Losartan | 74 | $1,015 | $14 |
| Diltiazem | 15 | $529 | $35 |
| Amlodipine Besylate | 60 | $448 | $7 |
| Hydralazine | 27 | $383 | $14 |
| Clopidogrel | 20 | $369 | $18 |
| Lisinopril | 31 | $335 | $11 |
| Furosemide | 29 | $327 | $11 |
| Carvedilol | 23 | $289 | $13 |
| Isosorbide Mononitrate Er | 13 | $288 | $22 |
| Metoprolol | 40 | $288 | $7 |
| Nitroglycerin | 13 | $160 | $12 |
| Hydrochlorothiazide | 16 | $129 | $8 |
2019: 21 drugs
| Eliquis | 26 | $28,858 | $1,110 |
| Multaq | 13 | $11,030 | $848 |
| Repatha Sureclick | 14 | $10,649 | $761 |
| Bystolic | 17 | $5,999 | $353 |
| Rosuvastatin | 63 | $3,047 | $48 |
| Metoprolol | 76 | $2,469 | $32 |
| Atorvastatin | 111 | $1,930 | $17 |
| Diltiazem 24hr Er (Cd) | 13 | $1,459 | $112 |
| Losartan | 66 | $957 | $15 |
| Isosorbide Mononitrate Er | 18 | $618 | $34 |
| Clopidogrel | 38 | $552 | $15 |
| Amlodipine Besylate | 58 | $479 | $8 |
| Amiodarone | 15 | $431 | $29 |
| Carvedilol | 32 | $421 | $13 |
| Lisinopril | 28 | $352 | $13 |
| Furosemide | 25 | $306 | $12 |
| Diltiazem | 16 | $239 | $15 |
| Hydrochlorothiazide | 18 | $152 | $8 |
| Metoprolol | 23 | $150 | $7 |
| Nitroglycerin | 13 | $146 | $11 |
| Spironolactone | 12 | $137 | $11 |
2018: 20 drugs
| Praluent | 28 | $33,820 | $1,208 |
| Eliquis | 35 | $32,980 | $942 |
| Multaq | 20 | $17,249 | $862 |
| Ranexa | 13 | $14,298 | $1,100 |
| Bystolic | 17 | $7,351 | $432 |
| Atorvastatin | 159 | $2,879 | $18 |
| Diltiazem 24hr Er (Cd) | 15 | $2,427 | $162 |
| Rosuvastatin | 61 | $2,268 | $37 |
| Metoprolol | 65 | $2,266 | $35 |
| Isosorbide Mononitrate Er | 36 | $823 | $23 |
| Carvedilol | 76 | $781 | $10 |
| Losartan | 69 | $708 | $10 |
| Clopidogrel | 56 | $692 | $12 |
| Lisinopril | 61 | $476 | $8 |
| Amlodipine Besylate | 73 | $442 | $6 |
| Amiodarone | 15 | $284 | $19 |
| Metoprolol | 34 | $198 | $6 |
| Nitroglycerin | 11 | $165 | $15 |
| Hydrochlorothiazide | 28 | $159 | $6 |
| Furosemide | 25 | $153 | $6 |
2017: 21 drugs
| Praluent | 26 | $31,888 | $1,226 |
| Ranexa | 16 | $14,897 | $931 |
| Eliquis | 23 | $14,380 | $625 |
| Bystolic | 30 | $10,433 | $348 |
| Rosuvastatin | 54 | $3,904 | $72 |
| Metoprolol | 57 | $3,186 | $56 |
| Atorvastatin | 162 | $2,440 | $15 |
| Amlodipine-Valsartan-Hctz | 12 | $1,210 | $101 |
| Losartan | 66 | $614 | $9 |
| Lisinopril | 79 | $607 | $8 |
| Carvedilol | 68 | $605 | $9 |
| Clopidogrel | 37 | $506 | $14 |
| Isosorbide Mononitrate Er | 17 | $472 | $28 |
| Amlodipine Besylate | 61 | $461 | $8 |
| Metoprolol | 41 | $274 | $7 |
| Spironolactone | 12 | $181 | $15 |
| Furosemide | 30 | $122 | $4 |
| Valsartan | 12 | $117 | $10 |
| Fosinopril | 11 | $106 | $10 |
| Atenolol | 13 | $85 | $7 |
| Hydrochlorothiazide | 15 | $56 | $4 |
2016: 23 drugs
| Ranexa | 24 | $13,597 | $567 |
| Eliquis | 18 | $7,773 | $432 |
| Bystolic | 33 | $7,040 | $213 |
| Crestor | 18 | $4,693 | $261 |
| Atorvastatin | 152 | $2,413 | $16 |
| Valsartan | 14 | $1,655 | $118 |
| Metoprolol | 50 | $912 | $18 |
| Rosuvastatin | 12 | $874 | $73 |
| Amlodipine-Valsartan | 13 | $653 | $50 |
| Isosorbide Mononitrate Er | 20 | $641 | $32 |
| Clopidogrel | 23 | $563 | $24 |
| Carvedilol | 61 | $440 | $7 |
| Losartan | 35 | $371 | $11 |
| Nitrostat | 12 | $370 | $31 |
| Hydralazine | 18 | $359 | $20 |
| Potassium Chloride | 17 | $309 | $18 |
| Amlodipine Besylate | 47 | $309 | $7 |
| Metoprolol | 45 | $304 | $7 |
| Diltiazem 24hr Er | 14 | $274 | $20 |
| Lisinopril | 52 | $242 | $5 |
| Furosemide | 19 | $157 | $8 |
| Hydrochlorothiazide | 18 | $67 | $4 |
| Atenolol | 11 | $29 | $3 |
2015: 15 drugs
| Crestor | 23 | $7,215 | $314 |
| Bystolic | 38 | $5,916 | $156 |
| Atorvastatin | 82 | $1,194 | $15 |
| Metoprolol | 38 | $820 | $22 |
| Cartia Xt | 26 | $419 | $16 |
| Clopidogrel | 13 | $366 | $28 |
| Carvedilol | 36 | $313 | $9 |
| Amlodipine Besylate | 19 | $211 | $11 |
| Lisinopril | 38 | $198 | $5 |
| Metoprolol | 28 | $198 | $7 |
| Nitrostat | 11 | $179 | $16 |
| Furosemide | 19 | $122 | $6 |
| Losartan | 17 | $120 | $7 |
| Spironolactone | 14 | $103 | $7 |
| Hydrochlorothiazide | 13 | $60 | $5 |
2014: 10 drugs
| Bystolic | 40 | $5,777 | $144 |
| Multaq | 12 | $3,083 | $257 |
| Atorvastatin | 76 | $1,658 | $22 |
| Carvedilol | 72 | $470 | $7 |
| Nitrostat | 18 | $289 | $16 |
| Isosorbide Mononitrate Er | 12 | $238 | $20 |
| Amlodipine Besylate | 19 | $196 | $10 |
| Furosemide | 24 | $155 | $6 |
| Hydrochlorothiazide | 26 | $133 | $5 |
| Lisinopril | 22 | $125 | $6 |
Money from drug and device companies
$2,443 in 2025
| 2025 | 2 | 2 | $2,356 | $2,443 |
| 2024 | 1 | 14 | None | $1,184 |
| 2023 | 1 | 3 | None | $291 |
| 2022 | 1 | 1 | None | $102 |
| 2021 | 2 | 4 | $3,570 | $3,664 |
| 2020 | 1 | 2 | $1,190 | $1,190 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Novartis Pharmaceuticals | None | $2,356 | 1 payment
|
| Amgen | Repatha | $87 | 1 payment
|
See all 2 published payments
| Novartis Pharmaceuticals | Consulting · 2025-11-21 | None | $2,356 |
| Amgen | Meals · 2025-04-01 | Repatha | $87 |
See earlier years (2024, 2023, 2022, 2021, 2020)
2024: $1,184
| Eli Lilly and | None | $1,184 | 14 payments
|
2023: $291
| Novartis Pharmaceuticals | Leqvio | $291 | 3 payments
|
2022: $102
| Novartis Pharmaceuticals | None | $102 | 1 payment
|
2021: $3,664
| Amgen | Repatha | $3,570 | 3 payments
|
| Novo Nordisk | None | $94 | 1 payment
|
2020: $1,190
| Amgen | Repatha | $1,190 | 2 payments
|
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| Eli Lilly and Company · A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study To Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(A) Who Have Established Atherosclerotic Cardiovascular Disease Or Are at Risk for A First Cardiovascular Event - Acclaim-Lp(A) · 2025 | Their institution | $445,593 |
| Novartis Pharmaceuticals Corporation · A Randomized Double-Blind, Placebo-Controlled, Multicenter Trial Assessing the Impact of Lipoprotein (A) Lowering With Tqj230 on Major Cardiovascular Events in Patients With Established Cardiovascular Disease · 2022 | Their institution | $128,213 |
| Novartis Pharmaceuticals Corporation · A Randomized Double-Blind, Placebo-Controlled, Multicenter Trial Assessing the Impact of Lipoprotein (A) Lowering With Tqj230 on Major Cardiovascular Events in Patients With Established Cardiovascular Disease · 2025 | Their institution | $98,817 |
| Novartis Pharmaceuticals Corporation · A Randomized Double-Blind, Placebo-Controlled, Multicenter Study To Evaluate the Efficacy, Safety and Tolerability of Pelacarsen (Tqj230) in US Black/African American & Hispanic Patient Populations With Elevated Lp(A) and Established Atherosclerotic Cardi · 2025 | Their institution | $95,479 |
| Novartis Pharmaceuticals Corporation · A Randomized Double-Blind, Placebo-Controlled, Multicenter Trial Assessing the Impact of Lipoprotein (A) Lowering With Tqj230 on Major Cardiovascular Events in Patients With Established Cardiovascular Disease · 2024 | Their institution | $87,116 |
| Novartis Pharmaceuticals Corporation · A Randomized Double-Blind, Placebo-Controlled, Multicenter Trial Assessing the Impact of Lipoprotein (A) Lowering With Tqj230 on Major Cardiovascular Events in Patients With Established Cardiovascular Disease · 2023 | Their institution | $64,184 |
| Novartis Pharmaceuticals Corporation · A Randomized Double-Blind, Placebo-Controlled, Multicenter Trial Assessing the Impact of Lipoprotein (A) Lowering With Tqj230 on Major Cardiovascular Events in Patients With Established Cardiovascular Disease · 2021 | Their institution | $54,606 |
| Novartis Pharmaceuticals Corporation · Multi-Center Cross-Sectional Epidemiological Study To Characterize the Prevalence and Distribution of Lipoprotein(A) Levels Among Patients With Established Cardiovascular Disease · 2021 | Their institution | $24,375 |
| Gilead Sciences, Inc. · Effect of Late Sodium Current Inhibition (Ranolazine) on Symptom and Quality of Life in Patients With Angina in the Absence of Obstructive Coronary Artery Disease: A Cohort Study · 2019 | Their institution | $21,429 |
| Novartis Pharmaceuticals Corporation · A Randomized Double-Blind, Placebo-Controlled, Multicenter Trial Assessing the Impact of Lipoprotein(A) Lowering With Pelacarsen (Tqj230) on the Progression of Calcific Aortic Valve Stenosis [Lp(A)Frontiers Cavs] · 2025 | Their institution | $17,419 |
| Novartis Pharmaceuticals Corporation · A Randomized Double-Blind, Placebo-Controlled, Multicenter Trial Assessing the Impact of Lipoprotein(A) Lowering With Pelacarsen (Tqj230) on the Progression of Calcific Aortic Valve Stenosis [Lp(A)Frontiers Cavs] · 2024 | Their institution | $13,521 |
| Novartis Pharmaceuticals Corporation · A Randomized Double-Blind, Placebo-Controlled, Multicenter Study To Evaluate the Efficacy, Safety and Tolerability of Pelacarsen (Tqj230) in US Black/African American & Hispanic Patient Populations With Elevated Lp(A) and Established Atherosclerotic Cardiovascular Disease · 2024 | Their institution | $5,439 |
| Eli Lilly and Company · A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study To Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(A) Who Have Established Atherosclerotic Cardiovascular Disease Or Are at Risk for A First Cardiovascular Event - Acclaim-Lp(A) · 2024 | Their institution | $3,220 |
| Amgen Inc. · A Double-Blind, Randomized, Placebo-Controlled, Multicenter Study Assessing Olpasiran Use To Prevent First Major Cardiovascular Events in Participants With Elevated Lipoprotein(A) · 2025 | Their institution | $1,732 |
| Novartis Pharmaceuticals Corporation · A Randomized Double-Blind, Placebo-Controlled, Multicenter Trial Assessing the Impact of Lipoprotein (A) Lowering With Tqj230 on Major Cardiovascular Events in Patients With Established Cardiovascular Disease · 2020 | Their institution | $183 |
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 76.5 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1063689941
- Licence
- CA A126558, IL 125-049596California A126558: Current · expires 2026-11-30Illinois 125049596: Cancelled
- Trained
- Ohio State University College of Medicine, 2005
- Group
- Stanford Health Care
- Video visits
- Lists video visits
- Gender
- Female
More record details
- Sole proprietor
- Yes
- Taxonomy
- Cardiology (207RC0000X); Internal medicine (207R00000X)
- Mailing address
- 300 Pasteur Dr, Stanford, CA, 94305
- NPI first listed
- 2008-05-10
- NPI last updated
- 2024-04-22
- NPI record certified
- 2024-04-22
This is when the NPI record was last certified, not a medical board exam.